-
The National Alliance of Proprietary Chinese Medicines is about to procure, and there are a large number of drugs or price reductions
Time of Update: 2022-09-20
According to this trend, the industry expects that in the future, under the background of the continuous expansion of the collection of proprietary Chinese medicines, companies that lay out innovative chinese medicines and have cost and variety advantages will easily stand out and achieve price for volume.
-
Heavy! The collection will be connected with the basic drug system, and the three types of drugs will not be included in the collection!
Time of Update: 2022-09-20
In the reply, the National Medical Insurance Bureau also revealed that in the procurement and assessment rules, the state will gradually improve the convergence of centralized procurement policies and the basic drug system, and promote medical institutions to give priority to the procurement and use of selected drugs on the basis of medication.
-
Beijing promotes the "going out" of traditional Chinese medicine to promote the coordinated development of industries such as pension and tourism
Time of Update: 2022-09-20
At the same time, relying on the Guang'anmen Hospital of the Chinese Academy of Chinese Medical Sciences, the "Beijing International Service Guidance and Evaluation Center for Traditional Chinese Medicine" was established as an industry policy research and management platform.
-
The Chinese medicine industry will face a new round of reshuffle!
Time of Update: 2022-09-20
In the long run, the collection of proprietary Chinese medicines will help the standardized development of the industry, improve the quality standard system, and is expected to benefit enterprises with advantages in raw material supply, product quality and cost control, and continuous R&D investment.
-
Many cities in Guangdong have launched free HPV vaccination for school-age girls
Time of Update: 2022-09-20
According to the "Guangdong Provincial Work Plan for Free Human Papillomavirus (HPV) Vaccination for School-age Girls (2022-2024)", the plan plans to enhance the awareness of cervical cancer prevention and control in target populations, improve the health level of women in the province, reduce the prevalence of cervical cancer, and gradually achieve 90% of girls under 15 years old to complete hpV preventive vaccine immunization by 2030.
-
Fosun Pharma was the first to reduce its holdings, but the pharmaceutical business grew against the trend, can it revitalize its glory in the future?
Time of Update: 2022-09-20
This is fosun pharma's third largest equity acquisition transaction in the past 10 years, in 2020 and 2021, BioNTech stock price increased by 140% and 216% respectively due to the new crown epidemic, and as of the end of 2021, this investment has brought more than 2.
-
Chinese Medicine Innovation Dragon Hair Wei! 3 exclusive proprietary Chinese medicines sold for 10 billion
Time of Update: 2022-09-20
2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: 100 million yuan) Source: Company Announcement Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields.
-
The innovation and upgrading of pharmaceutical enterprises has become the trend of the times, but these "shortcomings" still need to be filled
Time of Update: 2022-09-20
In addition, from the 2022 innovative drug enterprise report, more than 70% of the innovative pharmaceutical companies have increased their R&D investment, such as BeiGene, Hengrui, Junshi Biological, China Biopharmaceuticals, CSPC Pharmaceutical Research and Development, and Huang Pharmaceutical, which have invested more than 1 billion yuan.
-
China's annual production capacity of COVID-19 vaccines exceeds 7 billion doses, and the output exceeds 5.5 billion doses
Time of Update: 2022-09-20
(End) According to data disclosed by The Ministry of Industry and Information Technology of China on the 14th, China's annual production capacity of the new crown virus vaccine exceeds 7 billion doses and the output exceeds 5.
-
Npc deputies suggested that the cost of dental treatment be included in medical insurance The National Medical Insurance Bureau replied
Time of Update: 2022-09-20
Pharmaceutical The National Medical Security Bureau recently released on its official website its reply to Recommendation No. 3946 of the Fifth Session of the 13th National People's Congress (hereinafter referred to as the "Reply").
-
Hubei is expected to become a national center for the collection and collection of proprietary Chinese medicines! 42 proprietary Chinese medicines will soon be collected
Time of Update: 2022-09-20
By combining five major innovations, such as generic name procurement, comprehensive scoring shortlisting, combination of intra-product competition and inter-product competition to break the bid-rigging, introducing medical institution recognition indicators, and the lowest daily average treatment cost can be selected, the collection system solved the difficulties of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
-
Read it in one article: the specific differences between CRO, CMO, and CDMO
Time of Update: 2022-09-20
The various services provided by the company and their relationship with the final product are as follows: The main goal of the CDMO services provided by the company to customers is to successfully develop products such as pharmaceutical intermediates or APIs with commercial production feasibility in accordance with customer requirements.
-
Beijing biomedical whole industry chain open in the first half of the year approved innovative drugs and other national first
Time of Update: 2022-09-20
The "Implementation Plan for the Opening Up of the Whole Industry Chain of Biomedicine in Beijing" released at the beginning of this year put forward 17 50 policy measures and suggestions to accelera
-
Tianzhi Granule Clinical Release Expert Consensus and National Lecture Tour Kick-off Meeting was held in Beijing
Time of Update: 2022-09-15
Sponsored by the Beijing Neurology Society and co-organized by the Tianzhi Alliance for the Prevention and Treatment of Brain Dysfunction, the "Expert Consensus on the Clinical Application of Tianzhi
-
The standardized development of the Traditional Chinese Medicine Tablets industry is further! The total pass rate of sampling inspection reaches 98%
Time of Update: 2022-09-14
In order to purify the Chinese herbal medicine market, in February 2020, the State Food and Drug Administration issued the "Special Rectification Work Plan for Chinese Medicine Tablets", which put forward the overall objectives and work points for the special rectification of Chinese medicine tablets nationwide, and then successively introduced local special rectification work plans for Chinese medicine tablets, strengthened the frequency of sampling inspections, named and exposed unqualified pharmaceutical enterprises, and further standardized the development of the industry.
-
Mergers and acquisitions in the biomedical industry have become a trend! In the past three years, more than 900 cases have occurred, and the total amount of mergers and acquisitions has reached 100 billion
Time of Update: 2022-09-14
In addition, from the statistics of the past three years, more than 900 mergers and acquisitions in the biomedical industry have occurred, involving an amount of 171 billion yuan.
-
Since the beginning of this year, many pharmaceutical companies have been fined for environmental protection problems!
Time of Update: 2022-09-14
On February 9, 2022, Xinhua Pharmaceutical was fined 132,000 yuan by the Zibo Municipal Bureau of Ecology and Environment, and fined a total of 253,800 yuan for two environmental protection issues because it violated Article 18 of the Regulations on the Administration of Pollution Discharge Permits because the pollutant discharge methods and discharge destinations did not match the discharge permits.
-
Under the continuous investment in research and development, the income of many pharmaceutical companies in innovative drugs has reached a new high!
Time of Update: 2022-09-14
【Pharmaceutical Network Industry News】At present, the 2022 interim report of listed pharmaceutical companies has been disclosed one after another, and it can be seen from the reports of many pharmaceutical companies that through continuous investment in research and development, a number of pharmaceutical companies have achieved great results in innovative drugs, driving high revenue growth in the first half of the year.
-
National Medical Insurance Bureau: Accelerate the implementation of special treatment of oral implant medical service charges
Time of Update: 2022-09-14
organizedprocurement of medicinesdrugs According to the website of the National Medical Insurance Bureau, on September 6, the state organized a working conference on centralized procurement of medicines and a joint procurement meeting of drugs and consumables held by video.
-
Recently, a number of new drugs have been approved for new indications in China!
Time of Update: 2022-09-14
In China, rivaroxaban tablets have previously been approved for use in patients with chronic coronary artery disease or peripheral arterial disease to reduce the risk of major cardiovascular events; and indications for the treatment of venous thromboembolism and the prevention of recurrence in children and adolescents under 18 years of age.
